NCT07113522 - A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 26, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

May 7, 2027

Conditions

Inflammatory Bowel Disease (IBD)Ulcerative Colitis (UC)Crohn's Disease

Interventions

DRUG

MT-501

MT-501 Tablets

Trial Locations (16)

14618

RECRUITING

Mirador Therapeutics Selected Site, Rochester

29607

RECRUITING

Mirador Therapeutics Selected Site, Greenville

30078

RECRUITING

Mirador Therapeutics Selected Site, Snellville

32825

RECRUITING

Mirador Therapeutics Selected Site, Orlando

33176

RECRUITING

Mirador Therapeutics Selected Site, Miami

38018

RECRUITING

Mirador Therapeutics Selected Site, Cordova

53215

RECRUITING

Mirador Therapeutics Selected Site, Milwaukee

60026

RECRUITING

Mirador Therapeutics Selected Site, Glenview

64068

RECRUITING

Mirador Therapeutics Selected Site, Liberty

71105

RECRUITING

Mirador Therapeutics Selected Site, Shreveport

72205

RECRUITING

Mirador Therapeutics Selected Site, Little Rock

75230

RECRUITING

Mirador Therapeutics Selected Site, Dallas

75701

RECRUITING

Mirador Therapeutics Selected Site, Tyler

76092

RECRUITING

Mirador Therapeutics Selected Site, Southlake

78628

RECRUITING

Mirador Therapeutics Selected Site, Georgetown

79424

RECRUITING

Mirador Therapeutics Selected Site, Lubbock